ArticleOncotarget2017
Fractalkine/CX3CL1 induced intercellular adhesion molecule-1-dependent tumor metastasis through the CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 39 citations in OpenAlex.
- Rosavin modulates CX3CL1 secretion and osteoblast morphology under mineralizing conditions in vitro.Molecular biology reports · 2026Article
- CX3CL1-CX3CR1 signaling orchestrates malignant progression of prostate cancer through luminal progenitor-macrophage crosstalk.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Fractalkine (Chemokine CX3CL1) Signaling During Placentation and Placental Function.International journal of molecular sciences · 2026Review
- CX3CR1 and CCR2: dynamic myeloid cell states across inflammatory diseases with implications for oral health and disease.Frontiers in immunology · 2026Review
- Targeting chemokine signaling networks for therapeutics in skeletal disorders.Frontiers in endocrinology · 2025Review
- CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.International journal of molecular sciences · 2024Review
- Alterations in CX3CL1 Levels and Its Role in Viral Pathogenesis.International journal of molecular sciences · 2024Review
- Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link?International journal of molecular sciences · 2024Review
- CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity.Frontiers in immunology · 2024Article
- Exploring the role of miR-200 family in regulating CX3CR1 and CXCR1 in lung adenocarcinoma tumor microenvironment: implications for therapeutic intervention.Scientific reports · 2023Article
- CX3CL1 induces cell migration and invasion through ICAM-1 expression in oral squamous cell carcinoma cells.Journal of cellular and molecular medicine · 2023Article
- The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy.Frontiers in immunology · 2023Article
- Osteoid cell-derived chemokines drive bone-metastatic prostate cancer.Frontiers in oncology · 2023Review
- Expression of CX3CL1 and CCL28 in Spinal Metastases of Lung Adenocarcinoma and Their Correlation with Clinical Features and Prognosis.Journal of healthcare engineering · 2022Article
- Association ofInternational journal of environmental research and public health · 2021Article
- Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway.ACS omega · 2021Article
- CXJournal of cellular and molecular medicine · 2021Article
- CX3CR1 positively regulates BCR signaling coupled with cell metabolism via negatively controlling actin remodeling.Cellular and molecular life sciences : CMLS · 2020Article
- Increased expression of CX3CL1 and CX3CR1 in papillary thyroid carcinoma.Histology and histopathology · 2020Article
- Bone Microenvironment and Osteosarcoma Metastasis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common primary bone tumor in children and teens. The exact molecular mechanism underlying osteosarcoma progression still remains unclear. The CX3CL1/fractalkine has been implicated in various tumors but not in osteosarcoma. This study is the first to show that fractalkine promotes osteosarcoma metastasis by promoting cell migration. Fractalkine expression was higher in osteosarcoma cell lines than in normal osteoblasts. Fractalkine induced cell migration by upregulating intercellular adhesion molecule-1 (ICAM-1) expression via CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma cells. Knockdown of fractalkine expression markedly inhibited cell migration and lung metastasis in osteosarcoma. Finally, we showed a clinical correlation between CX3CL1 expression and ICAM-1 expression as well as tumor stage in human osteosarcoma tissues. In conclusion, our results indicate that fractalkine promotes cell migration and metastasis of osteosarcoma by upregulating ICAM-1 expression. Thus, fractalkine could serve a novel therapeutic target for preventing osteosarcoma metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.